We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
-$193M
Cap. Flow %
-7.88%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 63.96%
2 Consumer Discretionary 16.48%
3 Technology 3.08%
4 Real Estate 0.36%
5 Communication Services 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NIO icon
26
NIO
NIO
$12.1B
$23.5M 0.96%
4,600,000
-1,000,000
-18% -$7.09M
EPZM
27
DELISTED
Epizyme, Inc
EPZM
$21.7M 0.89%
+1,750,000
New +$19.6M
SAGE
28
DELISTED
Sage Therapeutics
SAGE
$19.9M 0.81%
125,000
+25,000
+25% +$3.62M
MDCO
29
DELISTED
Medicines Co
MDCO
$19.6M 0.8%
700,000
+300,000
+75% +$7.07M
PRQR icon
30
ProQR Therapeutics
PRQR
$251M
$19.4M 0.79%
1,400,000
– –
NBIX icon
31
CALL
Neurocrine Biosciences
NBIX
$18.3B
$17.6M 0.72%
+200,000
New +$16.7M
MLCO icon
32
CALL
Melco Resorts & Entertainment
MLCO
$2.22B
$16.9M 0.69%
750,000
+250,000
+50% +$5.43M
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$16.1M 0.66%
500,000
– –
AAL icon
34
CALL
American Airlines Group
AAL
$9.98B
$15.9M 0.65%
500,000
+200,000
+67% +$6.72M
BLUE
35
DELISTED
bluebird bio
BLUE
$15.7M 0.64%
7,720
-5,790
-43% -$10.2M
BOLD
36
DELISTED
Audentes Therapeutics, Inc
BOLD
$15.6M 0.64%
400,000
-200,000
-33% -$5.73M
XNCR icon
37
Xencor
XNCR
$1.47B
$15.5M 0.63%
500,000
– –
ASND icon
38
Ascendis Pharma A/S
ASND
$16.6B
$14.7M 0.6%
+125,000
New +$10.9M
DRNA
39
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$14.3M 0.59%
979,275
+454,275
+87% +$5.22M
AUTL
40
Autolus Therapeutics
AUTL
$386M
$14.2M 0.58%
450,000
-25,000
-5% -$711K
KLDO
41
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$13.7M 0.56%
+947,419
New +$13M
AGIO icon
42
CALL
Agios Pharmaceuticals
AGIO
$2.11B
$13.5M 0.55%
200,000
– –
MRTX
43
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.8M 0.52%
+175,000
New +$11.9M
ALLO icon
44
Allogene Therapeutics
ALLO
$639M
$11.6M 0.47%
400,000
– –
QCOM icon
45
CALL
Qualcomm
QCOM
$172B
$11.4M 0.47%
+200,000
New +$10.8M
SLDB icon
46
Solid Biosciences
SLDB
$817M
$11M 0.45%
80,000
+46,667
+140% +$11.7M
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$11M 0.45%
200,000
– –
KYNB
48
Kyntra Bio
KYNB
$27.9M
$10.9M 0.44%
8,000
-4,000
-33% -$5.42M
AXDX
49
DELISTED
Accelerate Diagnostics
AXDX
$10.5M 0.43%
50,000
– –
AMRN
50
CALL
Amarin Corp
AMRN
$298M
$10.4M 0.42%
+25,000
New +$9.02M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group withdrew a net $193M in Q1 2019, closing 19 positions and reducing 18 holdings. Its most notable exit was Clementia Pharmaceuticals Inc., an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in NVIDIA worth $75.4M.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.